CytomX Therapeutics Inc (NASDAQ:CTMX) has received an average recommendation of “Buy” from the thirteen research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $19.13.
A number of research analysts recently weighed in on CTMX shares. Zacks Investment Research lowered CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 15th. Guggenheim initiated coverage on CytomX Therapeutics in a research report on Wednesday, November 27th. They issued a “buy” rating and a $16.00 target price for the company. BidaskClub downgraded CytomX Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, October 1st. Mizuho reissued a “buy” rating and set a $16.00 price target on shares of CytomX Therapeutics in a research report on Monday, August 12th. Finally, Nomura restated a “buy” rating and set a $22.00 price objective on shares of CytomX Therapeutics in a research note on Sunday, August 11th.
CytomX Therapeutics stock traded up $0.16 on Tuesday, hitting $6.29. 283,934 shares of the stock traded hands, compared to its average volume of 454,322. CytomX Therapeutics has a 1 year low of $5.10 and a 1 year high of $19.75. The company has a debt-to-equity ratio of 0.31, a quick ratio of 4.40 and a current ratio of 4.40. The business’s fifty day simple moving average is $6.17 and its 200 day simple moving average is $8.88.
Several institutional investors have recently added to or reduced their stakes in CTMX. Bank of Montreal Can purchased a new position in CytomX Therapeutics during the second quarter valued at approximately $42,000. Aperio Group LLC acquired a new stake in CytomX Therapeutics during the 2nd quarter worth about $70,000. D.A. Davidson & CO. purchased a new stake in CytomX Therapeutics during the 2nd quarter valued at about $113,000. Man Group plc purchased a new stake in CytomX Therapeutics during the 3rd quarter valued at about $76,000. Finally, Metropolitan Life Insurance Co NY grew its stake in CytomX Therapeutics by 55.6% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 18,682 shares of the biotechnology company’s stock valued at $138,000 after purchasing an additional 6,673 shares during the last quarter. Institutional investors and hedge funds own 78.89% of the company’s stock.
About CytomX Therapeutics
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
Featured Story: How do analysts define an oversold condition?
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.